- Home
- Past Officers
Past Officers
Past Board Members, Advisors and Officers
2022 Board, Officers, and Advisors
Li-Fen Lee (President)
Dr. Li-Fen Lee is Founder, Chief Executive Officer and Board of Director of Apeximmune Therapeutics. Dr. Lee is deeply versed in the fields of immunology and immuno-oncology (IO) and a leader with over 20 years of drug development experience and expertise in multiple therapeutic areas in the biotech and pharmaceutical industry. Dr. Lee held leadership positions at Abbvie and NGM where she led the IO group and established the core IO infrastructure and helped build the IO pipeline. Dr. Lee started her career at Pfizer where she led a drug discovery group and made significant contributions to the development of therapeutic antibodies against IL-7R and various costimulatory molecules aimed at treating autoimmune diseases and cancer. Her work, which included several IND filings, patents and numerous high impact publications, was recognized with the prestigious Pfizer Achievement Award. Prior to joining industry, Dr. Lee held a faculty position at the Stanford University School of Medicine. She received her Ph.D. in Cancer Immunology at the University of North Carolina, Chapel Hill where she was a recipient of the Lineberger Graduate Fellow Award and completed postdoctoral training at Stanford University.
Dr. Lee joined CBA in 2007 and was the Chairperson in 2011, CBA Annual Conference. She likes hiking, swimming, traveling and reading in her leisure time.
Xinguo Jiang (Vice President and 2022 Annual Conference Chair)
Dr. Xinguo Jiang, is Associate Director/Sr. Principal Scientist at Apeximmune Therapeutics, where he leads the efforts in the novel target biology and translational medicine. Dr. Jiang has over 15 years of experience in translational research focusing on tumor immunity and autoimmune vascular inflammation with more than 40 peer-reviewed publications. He received his Ph.D. in Biochemistry from the University of Illinois at Urbana-Champaign, and a degree in Medicine from Zhejiang University in China. Dr. Jiang completed his post-doc training at Stanford University and currently also holds a PI position at VA Palo Alto supported by an NIH R01.
Dr. Jiang joined CBA in 2021. He used to play soccer and now is a passionate marathon runner.
Shu-en Wu (Operation and membership director)
Dr. Shu-en Wu is currently a scientist in Cepheid, a biotech company developing molecular diagnostic assays. Dr. Wu focused on the function of HCMV encoded G protein coupled-receptor in viral latency during his graduate work whereas his postdoctoral research studied how gut commensal bacteria regulate intestinal HDAC3 activity through metabolizing dietary component-phytate.
Dr. Wu received his Ph.D. degree from Department of Molecular Genetics, Biochemistry & Microbiology in University of Cincinnati and completed his postdoctoral training in Cincinnati Children’s Hospital Medical Center. He received his Master’s degree from Microbiology and Immunology in National Yang Ming University. He joined CBA in 2021.
Lindsey Xie (Secretary)
Ms. Xie is currently holding Sr. Manager position in Biometrics Department of Kite Pharma Inc., a Gilead company, with expertise in project management and SAS programming for statistical analysis to support company new drug development and FDA submission in oncology therapeutic area. She got her BS in Chemical Engineering from Hunan University and obtained MS in Statistics and MS in Bioengineering from University of Georgia. She has 10+ year hands-on working experience of statistical programming and project development in both pharmaceutical industries and CROs. She joined Chinese BioScience Association in 2017 and starting volunteering since then. She was the director of Publication for 2018 AC and responsible for AC Proceedings publication.
Katherine Wang (Treasurer)
Dr. Wang got her B.S. degree in Optics from Shandong University, and Ph.D. in Physics from Syracuse University. She worked as a research scientist in Neurodegenerative Diseases Center at University of Virginia. She has years of Hands-on experiences in optical engineering, DNA sequencing, protein purification, drug-protein interactions and cell culture. Professionally trained as a physicist, later she discovered that her real interest was in clinical data analysis. She is currently working as a SDTM programmer in Gilead Sciences after her years’ experience in clinical and statistical programming. Previously she worked as a certified advanced SAS programmer and data manager as well in clinical research organization. Katherine volunteered her time for CBA in 2009 and soon took over the responsibility of treasurer. She wrote articles for CBA Annual Conference news release in Chinese for three years. She also worked as a webmaster for www.cbasf.org during 2009 and 2010. In 2018, she helped publication in AC Proceedings. In her spare time, Katherine enjoys reading, writing, yoga and cuisine.
Ying Luan (Scientific Affair Director)
Ying Luan, Ph.D., MBA is currently Senior Staff Biostatistician at early multi-cancer detection company GRAIL Inc. Ying is an experienced pharmaceutical strategist and executor with strong analytical, communication, consulting, management and leadership skills. She has 14 years of pharmaceutical statistician experience working at Pharmacyclics/Abbvie, Jazz Pharmaceuticals, Teikoku Pharma USA, and Alza/Johnson & Johnson, in the therapeutic areas of immunology, Central Nervous System (CNS) and oncology. Her expertise includes statistics, clinical trial design, SME for licensing and M&A activities, regulatory strategy, submission, interactions with health authorities for new drug approval, label negotiation and expansion, managing biometrics CROs, partnership alliance, and clinical development. Ying got her Ph.D. in Statistics degree from the University of California, Riverside, and MBA from Wharton School, University of Pennsylvania. Her Master’s in Mathematics is from the University of Waterloo, Canada, and Bachelor’s from the Renmin University of China. Ying joined Chinese Bioscience Association SF in 2019 as a volunteer and supported a series of in-person and virtual activities.
Bing Liang (Sponsorship Director)
Bing Liang is an intellectual property attorney at Jones Day. She represents biotechnological and pharmaceutical companies on the procurement and protection of intellectual property. Her practice encompasses global patent portfolio development, management, and enforcement, particularly in the areas of biologics and diagnostics.
Ruei-Shian (Raymond) Wang (Communication Director)
Mr. Ruei-Shian (Raymond) Wang joins the LEAP fellowship program at Vivo Capital with a background in new drug discovery and development. Prior to Vivo, Ruei-Shian worked at R&D department of Allgenesis Biotherapeutics for more than seven years mainly focusing on preclinical study and manufacturing activity coordination in the neurological and ophthalmological projects. Prior to Allgenesis, Ruei-Shian served as product specialist at Yung-Shin Pharmaceutical Industrial managing the life cycle of generic medicine pipeline in neurological disorders
Mr. Wang is a registered pharmacist in Taiwan and practiced in Chang-Gung Memorial Hospital (Linkou branch). He received his M.Sc. in Pharmacology and a B.S. in Pharmacy from Taipei Medical University. He joined CBA in 2021.
Jing Folsom (Volunteer Director)
Dr. Folsom got her B.S degree in Biochemistry from Zhejiang University and Ph.D in Molecular Cellular Developmental Biology from Iowa State University. She moved to the bay area in 2013. She worked as a research associate in a biopharmaceutical company based in Sunnyvale, focused on animal model toxicity tests. Currently, she is a faculty member at Skyline Community College teaching Biology/Biotechnology. Dr. Folsom joined CBA in 2013 and volunteered in several events and annual conference.
Jia Jun Chia (Webmaster)
Ms. Chia is currently a Senior Research Associate at Gilead Sciences working in the Virology department as a researcher on the Hepatitis B cure program. Prior to moving to the Bay Area, she was a graduate student at the University of Washington Seattle, where she earned an MS in Bioengineering and investigated the role of vascular smooth muscle cells in the calcification of the brain vasculature. She also obtained a BS in Chemical and Biomolecular Engineering from Johns Hopkins University. She joined the Chinese Bioscience Association in 2017 as a volunteer to help with videography. In her spare time, she enjoys reading and spending time with her family.
2021 Board, Officers, and Advisors
Shuming Liu (President)
Dr. Shuming Liu received her doctoral degree in Medicine from Linköping Medical School in Sweden. She obtained her postdoctoral training at UCSF and worked as a scientist with expertise in molecular cell biology at BD Biosciences. Shuming is passionate about cancer research and education. She is currently the president of the Save Life and Talent Foundation, where she has devoted her time to reaching out to raise cancer awareness in communities such as schools and hospitals. Her educational seminars on cancer prevention, diagnosis, and treatment have attracted people from all over the world. Many of the attendees now belong to a growing online support group which she created to not only offer her counsel but to offer a community for those fighting cancer. Dr. Liu joined CBA at the beginning of 2019 and has been actively involved in organizing symposiums, social events, and the annual meeting. In her leisure time, she enjoys cooking, photography and traveling.
Frank Zhou (Operation and membership director)
Frank came to the United States from Shanghai, China. Intrinsically curious about human life, he earned a PhD in Biological Sciences at Carnegie Mellon University, where he studied functions of a tumor suppressor. Like many people in 2007, he was deeply touched by “The Last Lecture: Really Achieving Your Childhood Dreams” given by the late CMU computer science professor, Dr. Randy Pausch. After pushing back the frontiers of science for a decade, he realized the equal importance of preserving what we have in life besides exploring the unknowns in nature, especially after becoming a husband and a dad himself. Frank has been a CBA life time member since 2010 and volunteered for CBA for several years in different capacities.
Lindsey Xie (Secretary)
Ms. Xie is currently holding Sr. Manager position in Biometrics Department of Kite Pharma Inc., a Gilead company, with expertise in project management and SAS programming for statistical analysis to support company new drug development and FDA submission in oncology therapeutic area. She got her BS in Chemical Engineering from Hunan University and obtained MS in Statistics and MS in Bioengineering from University of Georgia. She has 10+ year hands-on working experience of statistical programming and project development in both pharmaceutical industries and CROs. She joined Chinese BioScience Association in 2017 and starting volunteering since then. She was the director of Publication for 2018 AC and responsible for AC Proceedings publication.
Katherine Wang (Treasurer)
Dr. Wang got her B.S. degree in Optics from Shandong University, and Ph.D. in Physics from Syracuse University. She worked as a research scientist in Neurodegenerative Diseases Center at University of Virginia. She has years of Hands-on experiences in optical engineering, DNA sequencing, protein purification, drug-protein interactions and cell culture. Professionally trained as a physicist, later she discovered that her real interest was in clinical data analysis. She is currently working as a SDTM programmer in Gilead Sciences after her years’ experience in clinical and statistical programming. Previously she worked as a certified advanced SAS programmer and data manager as well in clinical research organization. Katherine volunteered her time for CBA in 2009 and soon took over the responsibility of treasurer. She wrote articles for CBA Annual Conference news release in Chinese for three years. She also worked as a webmaster for www.cbasf.org during 2009 and 2010. In 2018, she helped publication in AC Proceedings. In her spare time, Katherine enjoys reading, writing, yoga and cuisine.
Shi-An Chen (Annual Conference Co-Chair)
Shi-An Chen is a Bio-X Stanford Interdisciplinary Graduate Fellow at Stanford University. He obtained his bachelor degree from National Taiwan University in Life Sciences. His research focus is scalable precision genome-editing technologies in fungal and mammalian systems. He joined CBA in 2018 and has been involved in organizing CBA events, as well as served as social chair since 2019. Shi-An is currently the president of the Asian American Graduate Student Association at Stanford University since 2019.
Dannis Chang (Annual Conference Co-Chair)
Dannis Chang, PharmD. is currently the Senior Director and Head of Global Medical Information and Scientific Communications at Halozyme Therapeutics, leading the development and establishment of the vision, overarching goals and objectives, and key strategic focus areas and tactics for Medical Information, Medical Communications, and Operations within Global Medical and Scientific Affairs. He received his undergraduate degree in Molecular and Cellular Biology from University of California – Berkeley, and upon graduation, he’s worked in project management at Genentech in the Translational and Molecular Oncology Division, as well as in research discovery and sales and marketing at LifeScan and AnaSpec Inc, respectively. Dannis also received a Doctor of Pharmacy (PharmD) degree from the University of Southern California and completed a post‐doctoral Fellowship with Novartis Oncology in US and Global Clinical Development and Scientific Affairs Division where he’s supported and led various efforts that involved US and Global Medical Information services, MSL Strategy and Operations, Managed Markets and Payer Access, and publications. During his fellowship, he also served as an adjunct faculty at the Ernest Mario School of Pharmacy at Rutgers University. Post fellowship training, Dannis joined Genentech as the Senior Product Lead in Medical Communications supporting Avastin in the lung, renal cell, and gynecologic cancer indications, and was accountable for the development and execution of various medical information duties. He also served as the Medical Science Director for Tecentriq in the genitourinary cancer medical team, where he’s made numerous contributions in preparation for the initial launch in 2L metastatic bladder cancer, and other launch readiness and post-market activities from a commercial and medical affairs capacity. Dannis was also the strategic program lead within Medical Business Operations, where he focused on developing system-wide capabilities to improve healthcare outcomes and enable the organization to apply the latest scientific and technological advances to resolve significant issues within the business, thus reducing operating costs and redundancies, and increase efficiencies across teams. Dannis joined Chinese Bioscience Association in 2018 as a volunteer and supported various activities such as the Cancer Immunotherapy Symposium, Member Picnic, and Annual Conference.
Ying Luan (Scientific Affair Director)
Ying Luan, Ph.D., MBA is currently Senior Staff Biostatistician at early multi-cancer detection company GRAIL Inc. Ying is an experienced pharmaceutical strategist and executor with strong analytical, communication, consulting, management and leadership skills. She has 14 years of pharmaceutical statistician experience working at Pharmacyclics/Abbvie, Jazz Pharmaceuticals, Teikoku Pharma USA, and Alza/Johnson & Johnson, in the therapeutic areas of immunology, Central Nervous System (CNS) and oncology. Her expertise includes statistics, clinical trial design, SME for licensing and M&A activities, regulatory strategy, submission, interactions with health authorities for new drug approval, label negotiation and expansion, managing biometrics CROs, partnership alliance, and clinical development. Ying got her Ph.D. in Statistics degree from the University of California, Riverside, and MBA from Wharton School, University of Pennsylvania. Her Master’s in Mathematics is from the University of Waterloo, Canada, and Bachelor’s from the Renmin University of China. Ying joined Chinese Bioscience Association SF in 2019 as a volunteer and supported a series of in-person and virtual activities.
Bing Liang (Sponsorship Director)
Bing Liang is an intellectual property attorney at Jones Day. She represents biotechnological and pharmaceutical companies on the procurement and protection of intellectual property. Her practice encompasses global patent portfolio development, management, and enforcement, particularly in the areas of biologics and diagnostics.
Scott Su (Communication Director)
Jing Folsom (Volunteer Director)
Dr. Folsom got her B.S degree in Biochemistry from Zhejiang University and Ph.D in Molecular Cellular Developmental Biology from Iowa State University. She moved to the bay area in 2013. She worked as a research associate in a biopharmaceutical company based in Sunnyvale, focused on animal model toxicity tests. Currently, she is a faculty member at Skyline Community College teaching Biology/Biotechnology. Dr. Folsom joined CBA in 2013 and volunteered in several events and annual conference.
Jia Jun Chia (Webmaster)
Ms. Chia is currently a Senior Research Associate at Gilead Sciences working in the Virology department as a researcher on the Hepatitis B cure program. Prior to moving to the Bay Area, she was a graduate student at the University of Washington Seattle, where she earned an MS in Bioengineering and investigated the role of vascular smooth muscle cells in the calcification of the brain vasculature. She also obtained a BS in Chemical and Biomolecular Engineering from Johns Hopkins University. She joined the Chinese Bioscience Association in 2017 as a volunteer to help with videography. In her spare time, she enjoys reading.
2020 Board, Officers, and Advisors
Dannis Chang (President)
Dannis Chang, PharmD. is currently the Senior Director and Head of Global Medical Information and Scientific Communications at Halozyme Therapeutics, leading the development and establishment of the vision, overarching goals and objectives, and key strategic focus areas and tactics for Medical Information, Medical Communications, and Operations within Global Medical and Scientific Affairs. He received his undergraduate degree in Molecular and Cellular Biology from University of California – Berkeley, and upon graduation, he’s worked in project management at Genentech in the Translational and Molecular Oncology Division, as well as in research discovery and sales and marketing at LifeScan and AnaSpec Inc, respectively. Dannis also received a Doctor of Pharmacy (PharmD) degree from the University of Southern California and completed a post‐doctoral Fellowship with Novartis Oncology in US and Global Clinical Development and Scientific Affairs Division where he’s supported and led various efforts that involved US and Global Medical Information services, MSL Strategy and Operations, Managed Markets and Payer Access, and publications. During his fellowship, he also served as an adjunct faculty at the Ernest Mario School of Pharmacy at Rutgers University. Post fellowship training, Dannis joined Genentech as the Senior Product Lead in Medical Communications supporting Avastin in the lung, renal cell, and gynecologic cancer indications, and was accountable for the development and execution of various medical information duties. He also served as the Medical Science Director for Tecentriq in the genitourinary cancer medical team, where he’s made numerous contributions in preparation for the initial launch in 2L metastatic bladder cancer, and other launch readiness and post-market activities from a commercial and medical affairs capacity. Dannis was also the strategic program lead within Medical Business Operations, where he focused on developing system-wide capabilities to improve healthcare outcomes and enable the organization to apply the latest scientific and technological advances to resolve significant issues within the business, thus reducing operating costs and redundancies, and increase efficiencies across teams. Dannis joined Chinese Bioscience Association in 2018 as a volunteer and supported various activities such as the Cancer Immunotherapy Symposium, Member Picnic, and Annual Conference.
Wenyi Chen (Annual Conference Chair)
Wenyi Chen, Ph.D. has been serving CBA since 2015. Wenyi is enthusiastic and has helped organize CBA activities such as summer picnics, workshops, and annual conferences. Wenyi served different roles in the organization throughout the years as the director of membership and alliances, board director and vice president. His current role is annual conference chair.
Professionally, he works as a Field Application Scientist to provide technical consultation in fluorescence activated cell sorting and automatic imaging cytometry. Wenyi has passion in helping fellow scientists and collaborates with them to develop and optimize assays to enhance research workflow.
Prior to his current job, he was a bench scientist himself and conducted research in the laboratory of Dr. Joseph Wu at Stanford University where he studied the mechanism of cardiac differentiation using human embryonic stem cells (hESCs) and conducted cell therapy studies using cardiac cells derived from hESCs.
Wenyi received his Ph.D. degree in Molecular, Cellular and Developmental Biology from the Ohio State University and is also an alumnus of Global Innovation Program, Stanford Graduate School of Business.
Katherine Wang (Treasurer)
Dr. Wang got her B.S. degree in Optics from Shandong University, and Ph.D. in Physics from Syracuse University. She worked as a research scientist in Neurodegenerative Diseases Center at University of Virginia. She has years of Hands-on experiences in optical engineering, DNA sequencing, protein purification, drug-protein interactions and cell culture. Professionally trained as a physicist, later she discovered that her real interest was in clinical data analysis. She is currently working as a SDTM programmer in Gilead Sciences after her years’ experience in clinical and statistical programming. Previously she worked as a certified advanced SAS programmer and data manager as well in clinical research organization. Katherine volunteered her time for CBA in 2009 and soon took over the responsibility of treasurer. She wrote articles for CBA Annual Conference news release in Chinese for three years. She also worked as a webmaster for www.cbasf.org during 2009 and 2010. In 2018, she helped publication in AC Proceedings. In her spare time, Katherine enjoys reading, writing, yoga and cuisine.
Yue Wang (Secretary)
Ms. Wang is currently Technical Project Scientist working at GENEWIZ with the expertise in DNA sequencing, molecular biology and technical consultation. She gained her PhD in animal Science in University of Delaware in 2014 and went for postdoc at USDA for avian flu diagnostic. She has 3+ year of industrial experience working at animal vaccine field and DNA sequencing field. Yue joined Chinese Bioscience Association in 2018 as volunteer.
Frank Zhou (Operations/Historian)
Frank came to the United States from Shanghai, China. Intrinsically curious about human life, he earned a PhD in Biological Sciences at Carnegie Mellon University, where he studied functions of a tumor suppressor. Like many people in 2007, he was deeply touched by “The Last Lecture: Really Achieving Your Childhood Dreams” given by the late CMU computer science professor, Dr. Randy Pausch. After pushing back the frontiers of science for a decade, he realized the equal importance of preserving what we have in life besides exploring the unknowns in nature, especially after becoming a husband and a dad himself. Frank has been a CBA life time member since 2010 and volunteered for CBA for several years in different capacities.
Shi-An Chen (Social Life / Volunteer Director)
Shuming Liu (Social Life / Volunteer Director)
Dr. Shuming Liu received her doctoral degree in Medicine from Linköping Medical School in Sweden. She obtained her postdoctoral training at UCSF and worked as a scientist with expertise in molecular cell biology at BD Biosciences. Shuming is passionate about cancer research and education. She is currently the president of the Save Life and Talent Foundation, where she has devoted her time to reaching out to raise cancer awareness in communities such as schools and hospitals. Her educational seminars on cancer prevention, diagnosis, and treatment have attracted people from all over the world. Many of the attendees now belong to a growing online support group which she created to not only offer her counsel but to offer a community for those fighting cancer. Dr. Liu joined CBA at the beginning of 2019 and has been actively involved in organizing symposiums, social events, and the annual meeting. In her leisure time, she enjoys cooking, gardening, and playing Candy Crush.
Ying Luan (Clinical and Scientific Affairs Director)
Lindsey Xie (Membership Director)
Ms. Xie is currently holding Sr. Manager position in Biometrics Department of Kite Pharma Inc., a Gilead company, with expertise in project management and SAS programming for statistical analysis to support company new drug development and FDA submission in oncology therapeutic area. She got her BS in Chemical Engineering from Hunan University and obtained MS in Statistics and MS in Bioengineering from University of Georgia. She has 10+ year hands-on working experience of statistical programming and project development in both pharmaceutical industries and CROs. She joined Chinese BioScience Association in 2017 and starting volunteering since then. She was the director of Publication for 2018 AC and responsible for AC Proceedings publication.
Po-Wei (Dennis) Lin (Strategic Alliances and Sponsorship Outreach Director)
Mr. Lin is GMP QA Scientist and Project Manager at SanBio Inc. (Mountain View, CA), and he is attending MBA program at University of California, Berkeley, Haas School of Business. Previously, Mr. Lin worked as researcher at Samsung Advanced Institute of Technology (Suwon, South Korea), Samsung Bioepis (Suwon, South Korea), and SanBio Inc. (Mountain View, CA), and he is first and co-author of several international patents and publications. Mr. Lin received his MSc degree from National Taiwan University, and he also holds the certificate of Project Management Professional (PMP). Due to his multicultural life experience, Mr. Lin speaks Chinese, Taiwanese, English, Korean, and Japanese. Mr. Lin volunteered for CBA since 2018 summer and was the 2019 CBA Secretary. Mr. Lin enjoys reading, jogging, learning new things, making new friends, and playing the guitar.
Bing Liang (Communications Director)
Bing Liang is an intellectual property attorney at Jones Day. She represents biotechnological and pharmaceutical companies on the procurement and protection of intellectual property. Her practice encompasses global patent portfolio development, management, and enforcement, particularly in the areas of biologics and diagnostics.
Yue Wu (Communications Director)
Huifang Li (Advisor Lead)
Dr. Li is a biotech entrepreneur on a mission to find new therapeutics for the treatment of neurodegenerative diseases. She received a Ph.D. degree in Cognition and Neuroscience from the University of Texas at Dallas and completed her postdoctoral training at Stanford University. After finishing her postdoctoral training, she stayed at Stanford University as a research scientist to further her interests in translational medicine. She has led several research projects targeting CNS disorders such as epilepsy, drug addiction and traumatic brain injury. Dr. Li has been a CBA board member since 2014 and in the past served as the Director of Public Relations (2014-2016), 2017 CBA Annual Conference Chair, 2017-2018 Vice President and 2019 President.
Jia Jun Chia (Webmaster)
Ms. Chia is currently a Senior Research Associate at Gilead Sciences working in the Virology department as a researcher on the Hepatitis B cure program. Prior to moving to the Bay Area, she was a graduate student at the University of Washington Seattle, where she earned an MS in Bioengineering and investigated the role of vascular smooth muscle cells in the calcification of the brain vasculature. She also obtained a BS in Chemical and Biomolecular Engineering from Johns Hopkins University. She joined the Chinese Bioscience Association in 2017 as a volunteer to help with videography. In her spare time, she enjoys reading.
2019 Board, Officers, and Advisors
Huifang Li (President)
Dr. Li is a biotech entrepreneur on a mission to find new therapeutics for the treatment of neurodegenerative diseases. She received a Ph.D. degree in Cognition and Neuroscience from the University of Texas at Dallas and completed her postdoctoral training at Stanford University. After finishing her postdoctoral training, she stayed at Stanford University as a research scientist to further her interests in translational medicine. She has led several research projects targeting CNS disorders such as epilepsy, drug addiction and traumatic brain injury. Dr. Li has been a CBA board member since 2014 and in the past served as the Director of Public Relations (2014-2016), 2017 CBA Annual Conference Chair and 2017-2018 Vice President.
Wenyi Chen (Vice President)
Dr. Chen has been serving CBA since 2015. Wenyi is enthusiastic and has helped many CBA activities such as summer picnic, workshops, and annual conferences. Wenyi was in charge of membership and social media in 2015 and 2016, and alliance liaison in 2017. In 2018, Wenyi has been elected and served as a board member. Professionally, he works as Field Application Scientist at NanoCellect Biomedical and provides technical consultation in fluorescence activated cell sorting. He has passion inhelping fellow scientists with better tools for better science. Prior to his current job, he was a bench scientist himself and conducted his research in the laboratory of Dr. Joseph Wu at Stanford University where he studied the mechanism of cardiac differentiation from human embryonic stem cells (hESCs) and the efficacy of the cell therapy using cardiac cells derived from hESCs. He is also an alumnus of GlobalInnovation Program at Stanford Graduate School of Business.
Susan Liang (Vice President)
Dr. Liang got her BSc degree in Applied Chemistry from Sun Yat-sen University, and PhD degree in Organic Chemistry from The Chinese University of Hong Kong. After graduation, Dr. Liang joined the Chemistry Department faculty as a Lecturer in Hong Kong Baptist University. In 2015, she moved to Bay Area and worked as a Project Manager at Sustainable Silicon Valley to promote on-site water recycling systems in both Santa Clara and San Mateo Counties. She’s now a postdoc in AbVision.
Katherine Wang (Treasurer)
Dr. Wang got her B.S. degree in Optics from Shandong University, and Ph.D. in Physics from Syracuse University. She worked as a research scientist in Neurodegenerative Diseases Center at University of Virginia. She has years of Hands-on experiences in optical engineering, DNA sequencing, protein purification, drug-protein interactions and cell culture. Professionally trained as a physicist, later she discovered that her real interest was in clinical data analysis. She is currently working as a SDTM programmer in Gilead Sciences after her years’ experience in clinical and statistical programming. Previously she worked as a certified advanced SAS programmer and data manager as well in clinical research organization. Katherine volunteered her time for CBA in 2009 and soon took over the responsibility of treasurer. She wrote articles for CBA Annual Conference news release in Chinese for three years. She also worked as a webmaster for www.cbasf.org during 2009 and 2010. In 2018, she helped publication in AC Proceedings. In her spare time, Katherine enjoys reading, writing, yoga and cuisine.
Po-Wei Lin (Secretary)
Mr. Lin is currently a researcher in the discovery research group of SanBio (Mountain View, CA), a company focusing on stem cell therapy and neuron regeneration medicine. Previously, Mr. Lin worked as research staff in Samsung Advanced Institute of Technology (SAIT, Korea), where he was actively involved in antibody new drug discovery and development. He also worked as Senior Scientist in cell line development group of Samsung Bioepis (Korea), where he attended several biosimilar projects. Mr. Lin is first and co-author of several international patents and publications, including the fields of new drug MoA study, combination treatment of oncologic targets, and angiogenesis. Mr. Lin received his MS degree in Zoology, molecular and cellular biology emphasis, from National Taiwan University. Due to his multicultural life experience, Mr. Lin speaks several languages, including Chinese, Taiwanese, English, Korean, and Japanese; therefore, he would like to help CBA bolster the interactions with its Korean and Japanese counterparts in the future. Mr. Lin volunteered his time for CBA in 2018 and helped the 2018 CBA conference proceeding composition and venue set up. Mr. Lin is CBA lifetime member. Mr. Lin enjoys reading, jogging, learning new things, making new friends, and playing the guitar.
Dannis Chang (Alliances)
Dannis Chang, PharmD. is currently the Senior Director and Head of Global Medical Information and Scientific Communications at Halozyme Therapeutics, leading the development and establishment of the vision, overarching goals and objectives, and key strategic focus areas and tactics for Medical Information, Medical Communications, and Operations within Global Medical and Scientific Affairs. He received his undergraduate degree in Molecular and Cellular Biology from University of California – Berkeley, and upon graduation, he’s worked in project management at Genentech in the Translational and Molecular Oncology Division, as well as in research discovery and sales and marketing at LifeScan and AnaSpec Inc, respectively. Dannis also received a Doctor of Pharmacy (PharmD) degree from the University of Southern California and completed a post‐doctoral Fellowship with Novartis Oncology in US and Global Clinical Development and Scientific Affairs Division where he’s supported and led various efforts that involved US and Global Medical Information services, MSL Strategy and Operations, Managed Markets and Payer Access, and publications. During his fellowship, he also served as an adjunct faculty at the Ernest Mario School of Pharmacy at Rutgers University. Post fellowship training, Dannis joined Genentech as the Senior Product Lead in Medical Communications supporting Avastin in the lung, renal cell, and gynecologic cancer indications, and was accountable for the development and execution of various medical information duties. He also served as the Medical Science Director for Tecentriq in the genitourinary cancer medical team, where he’s made numerous contributions in preparation for the initial launch in 2L metastatic bladder cancer, and other launch readiness and post-market activities from a commercial and medical affairs capacity. Dannis was also the strategic program lead within Medical Business Operations, where he focused on developing system-wide capabilities to improve healthcare outcomes and enable the organization to apply the latest scientific and technological advances to resolve significant issues within the business, thus reducing operating costs and redundancies, and increase efficiencies across teams. Dannis joined Chinese Bioscience Association in 2018 as a volunteer and supported various activities such as the Cancer Immunotherapy Symposium, Member Picnic, and Annual Conference.
Linya Wang (Sponsorship)
Dr. Wang is a microbiologist and cell biologist. She received her Ph.D. in Microbiology at National Taiwan University College of Medicine, and worked in Institute of Molecular Biology at Academia Sinica, Taiwan. She then finished her postdoctoral training in Molecular Microbiology and Immunology at University of Southern California, USA. Linya has switched from academic to industrial field. She is now working in AbVision inc., which focuses on therapeutic antibody drug discovery that can be applied to immunotherapy, cell therapy, and target therapy. She has also been involved in National Taiwan University Alumni Association as the President of Young Professional Group, Taiwanese Junior Chamber of Commerce as the Board of Director, Nextcon innovation startup as the organizer, and Southern California Taiwanese Biotechnology Association as the President. Linya has joined Chinese Bioscience Association (CBA) as a volunteer since July 2018. She leaded the registration team of the Annual Conference and upgraded the check-in process with app scanning system that not only speeds up the process but also benefits the future attendee analysis. She also participated in event promotion that brought in new members to CBA. Her skill set for event planning and connection building will benefits CBA as a BOD.
Jia Jun Chia (Newsletter)
Ms. Chia is currently a Senior Research Associate at Gilead Sciences working in the Virology department as a researcher on the Hepatitis B cure program. Prior to moving to the Bay Area, she was a graduate student at the University of Washington Seattle, where she earned an MS in Bioengineering and investigated the role of vascular smooth muscle cells in the calcification of the brain vasculature. She also obtained a BS in Chemical and Biomolecular Engineering from Johns Hopkins University. She joined the Chinese Bioscience Association in 2017 as a volunteer to help with videography. In her spare time, she enjoys reading.
Yue Wang (Public Relations)
Ms. Wang is currently Technical Project Scientist working at GENEWIZ with the expertise in DNA sequencing, molecular biology and technical consultation. She gained her PhD in animal Science in University of Delaware in 2014 and went for postdoc at USDA for avian flu diagnostic. She has 3+ year of industrial experience working at animal vaccine field and DNA sequencing field. Yue joined Chinese Bioscience Association in 2018 as volunteer.
Lindsey Xie (Publication)
Ms. Xie is currently holding Sr. Manager position in Biometrics Department of Kite Pharma Inc., a Gilead company, with expertise in project management and SAS programming for statistical analysis to support company new drug development and FDA submission in oncology therapeutic area. She got her BS in Chemical Engineering from Hunan University and obtained MS in Statistics and MS in Bioengineering from University of Georgia. She has 10+ year hands-on working experience of statistical programming and project development in both pharmaceutical industries and CROs. She joined Chinese BioScience Association in 2017 and starting volunteering since then. She was the director of Publication for 2018 AC and responsible for AC Proceedings publication.
Vivian Fu (Membership)
Dr. Fu has been serving CBA board for several terms since 2016. She is helping manage CBA membership. She received her Master degree in Immunology from Xi’an Jiaotong University and Ph.D. from the Department of Pathology and Cell Biology at the University of South Florida. After graduation, she joined Moffitt Cancer Center as a Postdoctoral fellow and worked on drug discovery and drug development. In 2013, she joined Bio-Rad as a Data Scientist and built Bio-Rad business intelligence platform and helped R&D, marketing, and sales teams on Business Development strategy, New Product Development, OEM decision, and marketing campaign. She has 10+ year hands-on working experience of Big Data, Cloud, and Machine Learning..
2018 Board, Officers, and Advisors
Board Members:
Dr. Susan Liang
Dr. Liang has been volunteering in CBA as sponsorship coordinator since March 2015. She got her BSc degree in Applied Chemistry from Sun Yat-sen University, and PhD degree in Organic Chemistry from The Chinese University of Hong Kong. After graduation, Dr. Liang joined the Chemistry Department faculty as a Lecturer in Hong Kong Baptist University. In 2015, she moved to Bay Area and worked as a Project Manager at Sustainable Silicon Valley to promote on-site water recycling systems in both Santa Clara and San Mateo Counties. She’s now seeking project management opportunities in biotech/pharmaceutical industries.
Dr. Katherine Wang
Dr. Wang got her B.S. degree in Optics from Shandong University, and Ph.D. in Physics from Syracuse University. She worked as research scientist in Neurodegenerative Diseases Center of University of Virginia. She has years of Hands-on experiences in optical engineering, DNA sequencing, protein purification, drug-protein interactions and cell culture. Professionally trained as physicist, later she discovered that her real interest is in clinical data analysis. She is currently working as SDTM programmer in Gilead Sciences after her years’ experience in clinical and statistical programming. Previously she worked as certified advanced SAS programmer and data manager as well in clinical research organization.
Katherine volunteered her time for CBA in 2009 and soon took over the responsibility of treasurer. She wrote articles for CBA Annual Conference news release in Chinese in three years. She also worked as webmaster for www.cbasf.org during 2009 and 2010.
In her spare time, Katherine enjoys reading, writing, cuisine and other activities, such as yoga and Scottish Country Dancing.
Dr. Vivian Fu
Dr. Fu received her Master degree in Immunology from Xi’an Jiaotong University, and Ph.D from Department of Pathology and Cell Biology at the University of South Florida. After graduation, she joined Moffitt Cancer Center as a Postdoc and worked on drug discovery and drug development. In 2013, Dr. Fu joined Bio-Rad as a Data Scientist and built Bio-Rad business intelligence platform and helped R&D, marketing, and sales teams on Business Development strategy, New Product Development, OEM decision, and marketing campaign.
Dr. Thomas Wei
Dr. Wei is now a postdoctoral researcher in Stanford University School of Medicine. His research currently focuses on new drug discovery and cardiovascular disease modeling using human induced pluripotent stem cells (iPSC). He is the inventor of several International patents on new small molecule drugs. Dr. Wei was supported by Stanford SPARK Program and joined Biomedical-Innovation and Entrepreneurship training course in Australia, 2014. He is a licensed and registered pharmacist in Taiwan, who has solid backgrounds and professional experimental skills in pharmacy, pharmacology and new drug discovery. Dr. Wei has been a volunteer of CBA since 2017. He also served Public Relationship Officer and then Secretary for CBA in 2017
Dr. Mark Chen
Dr. Chen is an immunologist with expertise in antibody design for therapeutic use and new vaccine discovery for the treatment of human cancers and infectious disease. He completed his Ph.D. in Immunology from Texas A&M University and has a track record of successful leadership roles in R&D, business development, and the marketing of therapeutic antibodies. Dr. Chen has been an active contributing Chinese BioScience Association board member since 2014. He has enthusiastically served CBA in the capacities of Secretary (2014, 2015) and Vice President (2016, 2017).
Dr. Huifang Li
Dr. Li is a biotech entrepreneur on a mission to find new therapeutics for the treatment of neurodegenerative diseases. She received a Ph.D. degree in Cognition and Neuroscience from the University of Texas at Dallas and completed her postdoctoral training at Stanford University. After finishing her postdoctoral training, she stayed at Stanford University as a research scientist to further her interests in translational medicine. She has led several research projects targeting CNS diseases such as epilepsy, drug addiction, and traumatic brain injury. Dr. Li has been a CBA board member since 2014 and in the past served as the Director of Public Relations and Vice President.
Dr. Wenyi Chen
Dr. Chen has been serving on CBA board for several terms since 2015. He helped organizing CBA workshop and annual conference. Wenyi currently works as Field Application Scientist at Nexcelom Bioscience and provides technical consultation in image cytometry, which has been widely used in immuno-oncology, 3D tumorspheroids and drug screening. Before joining Nexcelom in 2016, Wenyi conducted his research in the laboratory of Dr. Joseph Wu at Stanford University where he studied the mechanism of cardiac differentiation from human embryonic stem cells (hESCs) and the efficacy of the cell therapy using cardiac cells derived from hESCs. He received his Ph.D. from the Ohio State University and his B.S. from National Taiwan University.
Officers:
Mark Chen, President
Huifang Li, Vice President
Thomas Wei, Alliance Officer
Fu-Ning Hsu, Vice President. Dr. Fu-Ning Hsu received her Ph.D. in Life Sciences from National Chung Hsing University in Taiwan. Upon graduation, Dr. Hsu had been a postdoctoral researcher at Texas A&M University Health Science Center from 2012 to 2016. Her research focused on the regulation of androgen receptor in prostate cancer and the drug screening for disorders of lipid metabolism. In 2017, Dr. Hsu joined a startup biotech company, Bionova Scientific, as a Scientist. Dr. Hsu has become a board member and volunteer of Chinese Bioscience Association (CBA) in 2017 as the lead in publications.
Katherine Wang, Treasurer
Vivian Fu, Membership Director
Susan Liang, Sponsorship Director
Yen-Chi Wu, Public Relations Director. Dr. Laurie Wu is a molecular and genetic scientist and has good tracking record on the study of miRNAs and normal and cancer neural stem cell proliferation regulation. Dr. Wu received her Ph.D. from Indiana University Bloomington with extensive training in the field of RNA on 2014. After graduation, Dr. Wu then started her postdoctoral researcher in Stanford to apply the microRNA technology in therapeutic discovery before she joined BioVision Inc. in 2017. Now her work capacity and interests is to offer novel therapeutic strategies to fight human cancers. In 2017, Dr. Wu joined CBA as volunteer and actively contributed to assist on organizing CBA 20thanniversary conference.
Dr. Keith Cheung, Secretary. Dr. Cheung is a biochemist with expertise in protein chemistry. He received his B.S. and M.S. from UCSD, and Ph.D. in Biochemistry & Molecular Biology from UCLA. After he graduated, Dr. Cheung joined BioVision on 2016, and his research is focus on novel therapeutic discovery. Dr. Cheung has been actively contributing CBA since 2017.
Lindsey Xie, Publication. Ms. Xie is currently holding manager position in Biometrics Department of Gilead Sciences with expertise in project management and SAS programming for statistical analysis to support company new drug development and FDA submission in oncology therapeutic area. Ms. Xie got her BS in Chemical Engineering from Hunan University and obtained MS in Statistics and MS in Bioengineering from University of Georgia. She has 10+ year hands-on working experience of statistical programming and project development in both pharmaceutical industries and CROs. Ms. Xie joined Chinese BioScience Association in 2017 and was a volunteer for 2017 AC.
Advisors
Dr. Patrick Yang, Advisor (2017 CBA President). Dr.Yang is currently Principal Scientist at Relypsa, Inc. He has been working in bay area for many years in various pharmaceutical companies in the field of CMC including analytical development and quality control. Dr. Yang obtained his Ph. D. in pharmaceutical sciences from University of the Pacific, USA.
Patrick has been serving on CBA board for several terms since 2003. His roles include directors of membership, activity, and alliance. He successfully organized CBA education seminar “Dragon Parents Summit Talk”, and has been working as a committee member for Ho Family Scholarship. Besides CBA board member’s duty, Patrick also participated many other activities in the Bay Area. He helped organize a big literature seminar for Sichuan earthquake fundraising, led local student math team and science bowl teams, took judge and judge leader roles in Silicon Valley science fair, and served as CABS journal editor “Trends in Bio/Pharmaceutical Industry” for seven years. He is also an active writer with many readers.
Dr. Kai Zheng, Advisor (2016 CBA President). Dr. Kai Zheng received his Ph.D. from Department of Pharmaceutical Chemistry at the University of Kansas. After graduation, he joined Pharm. Technical Development department in Genentech at Oceanside, California and focused on formulation development of biotherapeutics at early stage. In 2011, Dr. Zheng joined Late Stage Pharmaceutical Development department in Genentech at South San Francisco site, where he focuses on Phase III and commercial formulation development of biotherapeutics and related regulatory filings. Dr. Zheng was vice president 2015.
He has been a board member and volunteer of Chinese Bioscience Association (CBA) in the last three years. His duty in CBA includes managing CBA membership and helping organizing numerous workshops and annual conferences.
Dr. Michelle Chen, Advisor (2014 CBA President). Dr. Chen is a biotech entrepreneur & executive with extensive experience and successful track record in corporate development, R&D and commercialization. Currently she is an executive director of business development at Merck. Prior to that she served as the head of corporate development of several biotech companies and helped them with fund raising, partnerships, product development strategy, press release and investor relationship.
Dr. Chen started her biotech career in R&D at Scios (now Johnson & Johnson) and later Abgenix (now Amgen) as a group leader. She then went on to gain marketing and business development experience at global companies such as Agilent, Roche Dx and Roche Pharma where she was responsible for global business development licensing, collaborations, M&A and external pharma partnerships in personalized medicine, Dx and drug development deals.
Dr. Chen obtained a PhD in Biochemistry from the University of Washington, followed by the post-doctoral work at UCSF. In addition she received bioinformatics training at Stanford University.
Dr. Lin Sun-Hoffman, Advisor (2013 CBA President). A founding partner in Liu, Zheng, Chen & Hoffman LLP, Dr. Lin Sun-Hoffman is a patent attorney with 20-year experience focused on innovative life sciences. Lin has deep knowledge in all aspects of patent practices, ranging from policy, patent preparation and prosecution, due diligence, opinion work, through licensing and technology transfer negotiation. In addition to her patent work, Lin has extensive experience with Chinese regulatory authorities, i.e., the Chinese FDA and the General Administration of Quality Supervision, Inspection and Quarantine (AQSIQ), and broader expertise in US and Chinese government affairs, serving clients ranging from start-up to Fortune-100.
Lin’s diverse background has prepared her to tackle the toughest challenges facing innovative life sciences companies today, starting with her time as a patent examiner at the United States Patent and Trademark Office (USPTO). She left USPTO to serve as managing patent counsel at Celera Genomics before joining the Life Technologies Corporation (formerly Applied Biosystems, now ThermoFisher). She is a frequent speaker in China, the US, and Europe, including participation at the invitation of USPTO to speak at SIPO and WIPO Conferences.
Lin also has over ten years of biomedical research experience including several years as a postdoctoral research fellow with several publications at the National Cancer Institute (NCI) of National Institutes of Health (NIH) in Frederick and Bethesda, Maryland. Lin currently serves as vice chair of LES International University-Industry-Government subcommittee, Bay Area Chapter head for BayHelix, Secretary General of US-China Green Energy Council. Lin was President of the Chinese Bioscience Association in Silicon Valley in 2013, and President of the Chinese Biopharmaceutical Association (CBA) 2008-2009. Lin also served as Chief Advisor for Asia at the Grocery Manufacturers Association (GMA) during 2011-2015, and Chief Advisor for Asia at Biotechnology Industry Organization’s (BIO) during 2009-2011.
Lin is also active in community activities including serving on the PTA executive council board (2015-2017) of Palo Alto School District, and teaches underprivileged students in rural area Yunnan China every summer. Lin obtained her J.D., from University of Maryland School of Law (Maryland, U.S.); Ph.D. in Biochemistry, Cell and Molecular Biology from the University of Nevada Reno (Nevada, U.S.); and B.S. in Biology, East China Normal University (Shanghai, China). She is admitted in Maryland and U.S. Patent and Trademark Office.
Dr. Shian-Jiun (SJ) Shih. Advisor (CBA Founding President). Dr. Shih is a consultant serving pharmaceutical and biotechnology clients, with more than twenty years’ of industrial experience and specializing in assay development and biomarkers. From 2009 to 2015 she worked at the Translational Medicine Research Centre, Merck Research Laboratories, Merck Sharp & Dohme, most recently as the Director and Site Lead of Molecular Biomarkers and Diagnostics. She lead 29 scientists with broad translational research skills, including immunoassays, nucleic acid-based assays and next generation sequencing, mass spectrometry, flow cytometry, cell-based assays, immunohistory chemistry, and bioinformatics. Her group was responsible for developing clinical biomarker assays to support early phase clinical trials, including those for Keytruda, as well as for collaborating with academic leaders in biomarker discovery, and for building primate disease models for target validation studies.
Prior to joining Merck, she was with Cell Genesys, a biotechnology company developing cell-based immunotherapy and oncolytic adenovirus-based gene therapy products from 2001 to 2008. As the Director of Assay Development there, her group developed quality control and clinical monitoring assays for phase 3 clinical trials, and conducted product characterization studies to answer inquires from FDA, and from regulatory authorities from other countries. During her time at Bayer Pharmaceuticals (2000-2001), SJ successfully developed liquid parenteral formulations and explored several novel drug delivery routes for biological drugs. From 1994 to 2000 she worked at Aventis (currently Sanofi) in various capacities, including characterization and purification of therapeutic monoclonal antibodies, development of a cell isolation medical device for bone marrow transplantation, liquid formulation and enhanced cellular delivery for gene therapy products. She started her industrial career in 1993 at BioSource (currently Invitrogen) and produced antibody reagents for research and in vitro diagnostic use.
SJ received a BS degree in Chemistry from National Taiwan University, and a Ph.D. in Biochemistry from University of Wisconsin–Madison, and completed her post-doctoral training at the department of Molecular Pharmacology at Stanford University.
Dr. Patty H Kiang, Advisor (2011 CBA President). Dr. Kiang is a consultant in Bio/Pharmaceutical industry supporting CMC Combination Products development and Quality systems. Patty was Head of Delivery device development for Genentech. Prior to Genentech, she held positions as Director, Drug Product Delivery for Schering Plough, and Director of Technology Development for West Pharmaceutical Services in Exton, PA. Patty is a member of the faculty of the PDA’s Training and Research Institute, where she teaches courses on Prefilled Syringe & injection devices and Parenteral Packaging; she has also served as committee or conference chair for USP Packaging Expert Committee, PDA Sterilization of Polymeric Materials Committee and PDA Global Prefilled Syringe & Injection Device Conference. She was president of the Chinese Bioscience Association in Northern CA – 2011, and continue serving as an advisor. She holds five patents in the field of polymeric surface coatings. She received a Ph.D. in Analytical Chemistry from Villanova University and holds an MBA from Pennsylvania State University.
2017 Board and Advisors
Dr. Patrick Yang, 2017 CBA President.Dr.Yang is currently Principal Scientist at Relypsa, Inc. He has been working in bay area for many years in various pharmaceutical companies in the field of CMC including analytical development and quality control. Dr. Yang obtained his Ph. D. in pharmaceutical sciences from University of the Pacific, USA.
Patrick has been serving on CBA board for several terms since 2003. His roles include directors of membership, activity, and alliance. He successfully organized CBA education seminar “Dragon Parents Summit Talk”, and has been working as a committee member for Ho Family Scholarship. Besides CBA board member’s duty, Patrick also participated many other activities in the Bay Area. He helped organize a big literature seminar for Sichuan earthquake fundraising, led local student math team and science bowl teams, took judge and judge leader roles in Silicon Valley science fair, and served as CABS journal editor “Trends in Bio/Pharmaceutical Industry” for seven years. He is also an active writer with many readers.
Dr. Mark Chen, Vice President. Dr. Chenis an immunologist with expertise in antibody design for therapeutic use and new vaccine discovery for the treatment of human
cancers and infectious disease. He completed his Ph.D. in Immunology
from Texas A&M University and has a track record of successful
leadership roles in R&D, business development, and the marketing of
therapeutic antibodies. Dr. Chen has been an active contributing Chinese
BioScience Association board member since 2014. He has
enthusiastically served CBA in the capacities of Secretary (2014, 2015)
and Vice President (2016).
Dr. Huifang Li, Vice President. Dr. Li is a biotech entrepreneur on a mission to find new therapeutics for the treatment of neurodegenerative diseases. She received a Ph.D. degree in Cognition and Neuroscience from the University of Texas at Dallas and completed her postdoctoral training at Stanford University. After finishing her postdoctoral training, she stayed at Stanford University as a research scientist to further her interests in translational medicine. She has led several research projects targeting CNS diseases such as epilepsy, drug addiction, and traumatic brain injury. Dr. Li has been a CBA board member since 2014 and in the past served as the Director of Public Relations.
Dr. Katherine Wang, Treasurer. Dr. Wang got her B.S. degree in Optics from Shandong University, and Ph.D. in Physics from Syracuse University. She worked as research scientist in Neurodegenerative Diseases Center of University of Virginia. She has years of Hands-on experiences in optical engineering, DNA sequencing, protein purification, drug-protein interactions and cell culture. Professionally trained as physicist, later she discovered that her real interest is in clinical data analysis. She is currently doing statistical programming after she led clinical programming projects at Gilead Sciences for around two years. Previously she worked as certified advanced SAS programmer and data manager as well in Clinovo. Katherine’s diligent work and enthusiasm have been well recognized. She enjoys reading, writing and Scottish Country Dancing.
Dr. Vivian Fu, CBA Membership. Dr. Fu received her Master degree in Immunology from Xi’an Jiaotong University, and Ph.D from Department of Pathology and Cell Biology at the University of South Florida. After graduation, she joined Moffitt Cancer Center as a Postdoc and worked on drug discovery and drug development. In 2013, Dr. Fu joined Bio-Rad as a Data Scientist and built Bio-Rad business intelligence platform and helped R&D, marketing, and sales teams on Business Development strategy, New Product Development, OEM decision, and marketing campaign.
Dr. Wenyi Chen, Alliance. Dr. Chen has been serving on CBA board for several terms since 2015. He helped organizing CBA workshop and annual conference. Wenyi currently works as Field Application Scientist at Nexcelom Bioscience and provides technical consultation in image cytometry, which has been widely used in immuno-oncology, 3D tumorspheroids and drug screening. Before joining Nexcelom in 2016, Wenyi conducted his research in the laboratory of Dr. Joseph Wu at Stanford University where he studied the mechanism of cardiac differentiation from human embryonic stem cells (hESCs) and the efficacy of the cell therapy using cardiac cells derived from hESCs. He received his Ph.D. from the Ohio State University and his B.S. from National Taiwan University.
Dr. Thomas Wei, Public Relations, Dr. Wei is now a postdoctoral researcher in Stanford University School of Medicine. His research currently focuses on drug discovery and cardiovascular disease modeling using human induced pluripotent stem cells (iPSC). He is the inventor of several International patents on new small molecule drugs and had experiences of technology transfer. Dr. Wei was supported by Stanford SPARK Program and joined Biomedical-Innovation and Entrepreneurship training course in Australia, 2014. He is a licensed and registered pharmacist in Taiwan, who has solid backgrounds and professional experimental skills in pharmacy, pharmacology and new drug discovery. Dr. Wei has been a board member and volunteer of Chinese Bioscience Association (CBA) since the end of 2016.
Dr. Michelle Chen, Advisor. Dr. Chen is a biotech entrepreneur & executive with extensive experience and successful track record in corporate development, R&D and commercialization. Currently she is an executive director of business development at Merck. Prior to that she served as the head of corporate development of several biotech companies and helped them with fund raising, partnerships, product development strategy, press release and investor relationship.
Dr. Chen started her biotech career in R&D at Scios (now Johnson & Johnson) and later Abgenix (now Amgen) as a group leader. She then went on to gain marketing and business development experience at global companies such as Agilent, Roche Dx and Roche Pharma where she was responsible for global business development licensing, collaborations, M&A and external pharma partnerships in personalized medicine, Dx and drug development deals.
Dr. Chen obtained a PhD in Biochemistry from the University of Washington, followed by the post-doctoral work at UCSF. In addition she received bioinformatics training at Stanford University.
Dr. Lin Sun-Hoffman, Advisor. A founding partner in Liu, Zheng, Chen & Hoffman LLP, Dr. Lin Sun-Hoffman is a patent attorney with 20-year experience focused on innovative life sciences. Lin has deep knowledge in all aspects of patent practices, ranging from policy, patent preparation and prosecution, due diligence, opinion work, through licensing and technology transfer negotiation.
In addition to her patent work, Lin has extensive experience with Chinese regulatory authorities, i.e., the Chinese FDA and the General Administration of Quality Supervision, Inspection and Quarantine (AQSIQ), and broader expertise in US and Chinese government affairs, serving clients ranging from start-up to Fortune-100.
Lin’s diverse background has prepared her to tackle the toughest challenges facing innovative life sciences companies today, starting with her time as a patent examiner at the United States Patent and Trademark Office (USPTO). She left USPTO to serve as managing patent counsel at Celera Genomics before joining the Life Technologies Corporation (formerly Applied Biosystems, now ThermoFisher). She is a frequent speaker in China, the US, and Europe, including participation at the invitation of USPTO to speak at SIPO and WIPO Conferences.
Lin also has over ten years of biomedical research experience including several years as a postdoctoral research fellow with several publications at the National Cancer Institute (NCI) of National Institutes of Health (NIH) in Frederick and Bethesda, Maryland. Lin currently serves as vice chair of LES International University-Industry-Government subcommittee, Bay Area Chapter head for BayHelix, Secretary General of US-China Green Energy Council. Lin was President of the Chinese Bioscience Association in Silicon Valley in 2013, and President of the Chinese Biopharmaceutical Association (CBA) 2008-2009. Lin also served as Chief Advisor for Asia at the Grocery Manufacturers Association (GMA) during 2011-2015, and Chief Advisor for Asia at Biotechnology Industry Organization’s (BIO) during 2009-2011.
Lin is also active in community activities including serving on the PTA executive council board (2015-2017) of Palo Alto School District, and teaches underprivileged students in rural area Yunnan China every summer.
Lin obtained her J.D., from University of Maryland School of Law (Maryland, U.S.); Ph.D. in Biochemistry, Cell and Molecular Biology from the University of Nevada Reno (Nevada, U.S.); and B.S. in Biology, East China Normal University (Shanghai, China). She is admitted in Maryland and U.S. Patent and Trademark Office
Dr. Shian-Jiun (SJ) Shih. Advisor (CBA Founding President). Dr. Shih is a consultant serving pharmaceutical and biotechnology clients, with more than twenty years’ of industrial experience and specializing in assay development and biomarkers.
From 2009 to 2015 she worked at the Translational Medicine Research Centre, Merck Research Laboratories, Merck Sharp & Dohme, most recently as the Director and Site Lead of Molecular Biomarkers and Diagnostics. She lead 29 scientists with broad translational research skills, including immunoassays, nucleic acid-based assays and next generation sequencing, mass spectrometry, flow cytometry, cell-based assays, immunohistory chemistry, and bioinformatics. Her group was responsible for developing clinical biomarker assays to support early phase clinical trials, including those for Keytruda, as well as for collaborating with academic leaders in biomarker discovery, and for building primate disease models for target validation studies.
Prior to joining Merck, she was with Cell Genesys, a biotechnology company developing cell-based immunotherapy and oncolytic adenovirus-based gene therapy products from 2001 to 2008. As the Director of Assay Development there, her group developed quality control and clinical monitoring assays for phase 3 clinical trials, and conducted product characterization studies to answer inquires from FDA, and from regulatory authorities from other countries.
During her time at Bayer Pharmaceuticals (2000-2001), SJ successfully developed liquid parenteral formulations and explored several novel drug delivery routes for biological drugs. From 1994 to 2000 she worked at Aventis (currently Sanofi) in various capacities, including characterization and purification of therapeutic monoclonal antibodies, development of a cell isolation medical device for bone marrow transplantation, liquid formulation and enhanced cellular delivery for gene therapy products. She started her industrial career in 1993 at BioSource (currently Invitrogen) and produced antibody reagents for research and in vitro diagnostic use.
SJ received a BS degree in Chemistry from National Taiwan University, and a Ph.D. in Biochemistry from University of Wisconsin–Madison, and completed her post-doctoral training at the department of Molecular Pharmacology at Stanford University.
Dr. Patty H Kiang, Advisor. Dr. Kiang is a consultant in Bio/Pharmaceutical industry supporting CMC Combination Products development and Quality systems.
Patty was Head of Delivery device development for Genentech. Prior to Genentech, she held positions as Director, Drug Product Delivery for Schering Plough, and Director of Technology Development for West Pharmaceutical Services in Exton, PA. Patty is a member of the faculty of the PDA’s Training and Research Institute, where she teaches courses on Prefilled Syringe & injection devices and Parenteral Packaging; she has also served as committee or conference chair for USP Packaging Expert Committee, PDA Sterilization of Polymeric Materials Committee and PDA Global Prefilled Syringe & Injection Device Conference. She was president of the Chinese Bioscience Association in Northern CA – 2011, and continue serving as an advisor. She holds five patents in the field of polymeric surface coatings. She received a Ph.D. in Analytical Chemistry from Villanova University and holds an MBA from Pennsylvania State University.
2016 Board and Advisors
Kai Zheng, PhD, 2016 CBA President Dr. Kai Zheng received his Ph.D. from Department of Pharmaceutical Chemistry at the University of Kansas. After graduation, he joined Pharm. Technical Development department in Genentech at Oceanside, California and focused on formulation development of biotherapeutics at early stage. In 2011, Dr. Zheng joined Late Stage Pharmaceutical Development department in Genentech at South San Francisco site, where he focuses on Phase III and commercial formulation development of biotherapeutics and related regulatory filings. Dr. Zheng was vice president 2015.
He has been a board member and volunteer of Chinese Bioscience Association (CBA) in the last three years. His duty in CBA includes managing CBA membership and helping organizing numerous workshops and annual conferences.
Mark Chen, PhD, 2016 CBA Vice President
Dr. Wenyi Chen, Membership
Dr. Katherine Wang, Treasurer Katherine Wang got her B.S. degree in Optics from Shandong University, and Ph.D. in Physics from Syracuse University. She worked as research scientist in Neurodegenerative Diseases Center of University of Virginia. She has years of Hands-on experiences in optical engineering, DNA sequencing, protein purification, drug-protein interactions and cell culture. Professionally trained as physicist, later she discovered that her real interest is in clinical data analysis. She is currently doing statistical programming after she led clinical programming projects at Gilead Sciences for around two years. Previously she worked as certified advanced SAS programmer and data manager as well in Clinovo. Katherine’s diligent work and enthusiasm have been well recognized. She enjoys reading, writing and Scottish Country Dancing.
Dr. Patrick Yang, Alliance Dr. Patrick Yang is currently Principal Scientist at Relypsa, Inc. He has been working in bay area for many years in various pharmaceutical companies in the field of CMC/analytical development. Dr. Yang obtained his Ph. D. in pharmaceutical sciences from University of the Pacific, USA. He has previously served on CBA board several terms.
Shih-Chen Chang, PhD, Publications (2015 CBA President) Shih-Chen currently worked in Genentech as a senior Real World Data Scientist supporting infectious disease (ID) area since September 2011. Before he joined in the company, he worked at AstraZeneca for ~5 years in global epidemiology department, covering oncology and ID therapeutic areas, and spent 3.5 years for his post-doctorate training on cancer epidemiology at National Cancer Institute. He obtained his PhD in School of Public Health, Johns Hopkins, and Master of Science and Undergraduate degree from National Taiwan University.
Soon after his move to SF Bay area, Shih-Chen participated in his first 2011 CBA annual meeting and joined the CBA Committee board in 2012, supporting publication and sponsorship. He subsequently took the role as vice president in 2013 and chaired the annual conference. Shih-Chen has great passion to serve the community. Looking forward he hopes to continue building the foundation for the growing CBA, and promote this exciting organization to the greater Bay area bioscience communities.
Hui Fang Li, Public relationship
Caesar Ho, Scholarship
Yuan Zhang, Secretary
Mr. Frank Lin, Taiwan Liaison Mr. Frank Lin is the Regional Sales Marketing Director at Specialdeals.com, a VC funded startup a deal-of-the-day website that features discounted gift certificates usable at local or national companies. Frank Lin is the Regional Marketing Director in US and General Manager in Asia Pacific at Matchbin, Inc, a Web 2.0 Content Management System (CMS) provider for newspaper/radio station/magazine industry. Prior to that, Mr. Lin was a Sales Operation / Marketing Specialist at VeriSilicon, a Fabless Semiconductor company. Mr. Lin now is the Marketing Manager at GBC (www.gbc.com.tw). Mr. Lin received his B.A. degree in Electrical and Computer Engineering from Purdue University and an MBA from Santa Clara University.
Mr. Andrew Teng, Taiwan Liaison Currently acting as C.S.O. at Sunwell Scientific Inc. Mr. Teng has more than 16 years of general management experience in the fields of semiconductor and Bio Science. His broad background includes P&L, operational, BD, product development, marketing, IP protection and M&A. He was a Managing Director at Ecos Lab Co. Prior to joining Ecos Lab, Mr. Teng held a senior positions with Encepho Pharmaceutical as V.P. of Business Development. Mr. Teng has extensive international experience having had direct responsibility for business development and strategic planning in Greater China. Mr. Teng has a B.S. degree from San Jose State University. Currently studying PhD in Industrial Economics at Jinan University, China.
Dr. Michelle Chen, Advisor Dr. Chen is a biotech entrepreneur & executive with extensive experience in biopharma, diagnostics and life sciences. She has a track record of successful leadership roles in business development, marketing and R&D. Most recently she was a business development executive at Hoffmann-La Roche responsible for global oncology licensing, collaborations and M&A. Prior to this role, she was involved in the personalized medicine effort for Roche. Dr. Chen started her biotech career in early drug discovery& development at Scios and later Abgenix as a group leader working on the assay development of antibody drugs. She then went on to gain commercial experience at Agilent Technologies and Applied Biosystems respectively. Dr. Chen received a PhD in Biochemistry from the University of Washington, followed by the post-doctoral work at UCSF and bioinformatics training at Stanford University. She has been a CBA board member, advisor and volunteer in the last five years and a FAST program advisor for BayBio dedicated to help biotech start-ups grow and succeed. She was the president of CBA 2014.
Dr. Lin Sun-Hoffman, Advisor Dr. Sun-Hoffman is a licensed patent attorney and advises on issues related to intellectual property and technology transfer matters. She also consults on biotechnology and pharmaceutical business-related matters. She helps businesses expand into China through providing strategic and practical advice on issues as diverse as government relations, research and/or business partnerships between Chinese and American companies, intellectual property protection and drug regulatory matters. She previously worked for Life Technologies/ABI, BIO, Celera Genomics, US Patent and Trademark Office and National Institutes of Health. She is the former president of Chinese Biopharmaceutical Association based in Washington DC, currently serves on board of US China Green Energy Council, a member of Bayhelix. Dr. Sun-Hoffman has a PhD in Biochemistry/Cell and Molecular Biology. She was the president of CBA 2013.
Shian-Jiun (SJ) Shih, Ph.D. Advisor (CBA Founding President) SJ Shih is a consultant serving pharmaceutical and biotechnology clients, with more than twenty years’ of industrial experience and specializing in assay development and biomarkers.
From 2009 to 2015 she worked at the Translational Medicine Research Centre, Merck Research Laboratories, Merck Sharp & Dohme, most recently as the Director and Site Lead of Molecular Biomarkers and Diagnostics. She lead 29 scientists with broad translational research skills, including immunoassays, nucleic acid-based assays and next generation sequencing, mass spectrometry, flow cytometry, cell-based assays, immunohistory chemistry, and bioinformatics. Her group was responsible for developing clinical biomarker assays to support early phase clinical trials, including those for Keytruda, as well as for collaborating with academic leaders in biomarker discovery, and for building primate disease models for target validation studies.
Prior to joining Merck, she was with Cell Genesys, a biotechnology company developing cell-based immunotherapy and oncolytic adenovirus-based gene therapy products from 2001 to 2008. As the Director of Assay Development there, her group developed quality control and clinical monitoring assays for phase 3 clinical trials, and conducted product characterization studies to answer inquires from FDA, and from regulatory authorities from other countries.
During her time at Bayer Pharmaceuticals (2000-2001), SJ successfully developed liquid parenteral formulations and explored several novel drug delivery routes for biological drugs. From 1994 to 2000 she worked at Aventis (currently Sanofi) in various capacities, including characterization and purification of therapeutic monoclonal antibodies, development of a cell isolation medical device for bone marrow transplantation, liquid formulation and enhanced cellular delivery for gene therapy products. She started her industrial career in 1993 at BioSource (currently Invitrogen) and produced antibody reagents for research and in vitro diagnostic use.
SJ received a BS degree in Chemistry from National Taiwan University, and a Ph.D. in Biochemistry from University of Wisconsin–Madison, and completed her post-doctoral training at the department of Molecular Pharmacology at Stanford University.
Cindy Liu Advisor
Cheni Kwok Advisor
Julie Yang Advisor
Kelley Liu Advisor
Patty Kiang Advisor
Sydney Chen Advisor
Ta-Kai Li Advisor
2015 Boards and Advisors
Shih-Chen Chang, PhD, 2015 CBA President Shih-Chen currently worked in Genentech as a senior Real World Data Scientist supporting infectious disease (ID) area since September 2011. Before he joined in the company, he worked at AstraZeneca for ~5 years in global epidemiology department, covering oncology and ID therapeutic areas, and spent 3.5 years for his post-doctorate training on cancer epidemiology at National Cancer Institute. He obtained his PhD in School of Public Health, Johns Hopkins, and Master of Science and Undergraduate degree from National Taiwan University.
Soon after his move to SF Bay area, Shih-Chen participated in his first 2011 CBA annual meeting and joined the CBA Committee board in 2012, supporting publication and sponsorship. He subsequently took the role as vice president in 2013 and chaired the annual conference. Shih-Chen has great passion to serve the community. Looking forward he hopes to continue building the foundation for the growing CBA, and promote this exciting organization to the greater Bay area bioscience communities.
Kai Zheng, PhD, 2015 CBA Vice President Dr. Kai Zheng received his Ph.D. from Department of Pharmaceutical Chemistry at the University of Kansas. After graduation, he joined Pharm. Technical Development department in Genentech at Oceanside, California and focused on formulation development of biotherapeutics at early stage. In 2011, Dr. Zheng joined Late Stage Pharmaceutical Development department in Genentech at South San Francisco site, where he focuses on Phase III and commercial formulation development of biotherapeutics and related regulatory filings.
He has been a board member and volunteer of Chinese Bioscience Association (CBA) in the last three years. His duty in CBA includes managing CBA membership and helping organizing numerous workshops and annual conferences.
Cheni Kwok, PhD, 2015 CBA Vice President Dr. Kwok is a Managing Partner and Founder of Linear Dreams LLC, a management consultancy and valuation software firm specialized in corporate strategy, business/corporate development, portfolio analysis, and valuation services for the life science industry.
Prior to founding Linear Dreams LLC, Dr. Kwok served as Senior Vice President, Corporate Development at Poniard Pharmaceuticals Inc., where she established corporate and business development, strategic and commercial planning, new product planning, competitive intelligence and forecasting functions. Previously, Dr. Kwok was Director of Business Development at Celera Genomics Inc., where she led the business development efforts for Celera’s small molecule therapeutics. Dr. Kwok held business development positions of increasing responsibility for Exelixis Inc., where she initiated multiple partnerships and served as the alliance manager for the GlaxoSmithKline PLC (GSK) collaboration. Prior to joining Exelixis Inc., Dr. Kwok held various research management, technology assessment and alliance management roles at SmithKline Beecham PLC (now GSK).
Dr. Kwok received a bachelor’s degree in biotechnology from the Imperial College of Science, Technology and Medicine, University of London, UK, and a Ph.D. in human molecular genetics from the University of Cambridge, UK. Dr. Kwok has earned the Certified Licensing Professional (CLP) credential awarded by the Licensing Executives Society. Dr Kwok is currently serving as the co-chair of Business and Career Development Committee of Chinese-American BioPharmaceutical Society (CABS), Marketing & Outreach Committee of CLP and Leadership Council Member (Chinese Unit) of the American Cancer Society. Dr. Kwok was born in Taiwan and grew up in Singapore.
Dr. Michelle Chen, Advisor Dr. Chen is a biotech entrepreneur & executive with extensive experience in biopharma, diagnostics and life sciences. She has a track record of successful leadership roles in business development, marketing and R&D. Most recently she was a business development executive at Hoffmann-La Roche responsible for global oncology licensing, collaborations and M&A. Prior to this role, she was involved in the personalized medicine effort for Roche. Dr. Chen started her biotech career in early drug discovery& development at Scios and later Abgenix as a group leader working on the assay development of antibody drugs. She then went on to gain commercial experience at Agilent Technologies and Applied Biosystems respectively. Dr. Chen received a PhD in Biochemistry from the University of Washington, followed by the post-doctoral work at UCSF and bioinformatics training at Stanford University. She has been a CBA board member, advisor and volunteer in the last five years and a FAST program advisor for BayBio dedicated to help biotech start-ups grow and succeed. She was the president of CBA 2014.
Dr. Lin Sun-Hoffman, Advisor Dr. Sun-Hoffman is a licensed patent attorney and advises on issues related to intellectual property and technology transfer matters. She also consults on biotechnology and pharmaceutical business-related matters. She helps businesses expand into China through providing strategic and practical advice on issues as diverse as government relations, research and/or business partnerships between Chinese and American companies, intellectual property protection and drug regulatory matters. She previously worked for Life Technologies/ABI, BIO, Celera Genomics, US Patent and Trademark Office and National Institutes of Health. She is the former president of Chinese Biopharmaceutical Association based in Washington DC, currently serves on board of US China Green Energy Council, a member of Bayhelix. Dr. Sun-Hoffman has a PhD in Biochemistry/Cell and Molecular Biology. She was the president of CBA 2013.
Dr. Katherine Wang, Treasurer Katherine Wang got her B.S. degree in Optics from Shandong University, and Ph.D. in Physics from Syracuse University. She worked as research scientist in Neurodegenerative Diseases Center of University of Virginia. She has years of Hands-on experiences in optical engineering, DNA sequencing, protein purification, drug-protein interactions and cell culture. Professionally trained as physicist, later she discovered that her real interest is in clinical data analysis. She is currently doing statistical programming after she led clinical programming projects at Gilead Sciences for around two years. Previously she worked as certified advanced SAS programmer and data manager as well in Clinovo. Katherine’s diligent work and enthusiasm have been well recognized. She enjoys reading, writing and Scottish Country Dancing.
Mr. Frank Lin, Taiwan Liaison Mr. Frank Lin is the Regional Sales Marketing Director at Specialdeals.com, a VC funded startup a deal-of-the-day website that features discounted gift certificates usable at local or national companies. Frank Lin is the Regional Marketing Director in US and General Manager in Asia Pacific at Matchbin, Inc, a Web 2.0 Content Management System (CMS) provider for newspaper/radio station/magazine industry. Prior to that, Mr. Lin was a Sales Operation / Marketing Specialist at VeriSilicon, a Fabless Semiconductor company. Mr. Lin now is the Marketing Manager at GBC (www.gbc.com.tw). Mr. Lin received his B.A. degree in Electrical and Computer Engineering from Purdue University and an MBA from Santa Clara University.
Mr. Andrew Teng, Taiwan Liaison Currently acting as C.S.O. at Sunwell Scientific Inc. Mr. Teng has more than 16 years of general management experience in the fields of semiconductor and Bio Science. His broad background includes P&L, operational, BD, product development, marketing, IP protection and M&A. He was a Managing Director at Ecos Lab Co. Prior to joining Ecos Lab, Mr. Teng held a senior positions with Encepho Pharmaceutical as V.P. of Business Development. Mr. Teng has extensive international experience having had direct responsibility for business development and strategic planning in Greater China. Mr. Teng has a B.S. degree from San Jose State University. Currently studying PhD in Industrial Economics at Jinan University, China.
Dr. Patrick Yang, Alliance Dr. Patrick Yang is currently Principal Scientist at Relypsa, Inc. He has been working in bay area for many years in various pharmaceutical companies in the field of CMC/analytical development. Dr. Yang obtained his Ph. D. in pharmaceutical sciences from University of the Pacific, USA. He has previously served on CBA board several terms.
Dr. Anthony Liou, Publications Dr. Anthony K. Liou obtained his Ph.D. in Molecular Cell Biology from the Institute of Cancer Research, University of London. Upon graduation, Dr. Liou had been a research fellow at UCSF and National University of Singapore. Then, he became a junior faculty at the University of Pittsburgh. His research focused on the identification and elucidation of key protein targets and their mechanism in regulating neuronal degeneration in various neurological disorders. In the summer of 2014, Dr. Liou joined Linear Dreams LLC as an Analyst.
Dr. Liou has become a board member and volunteer of Chinese Bioscience Association (CBA) in 2015 as the lead in publications. He is the Editor in Chief of the Annual Conference program.
Dr. Wenyi Chen, Membership
Mark Chen, Secretary
Hui Fang Li, Press relationship
Jing Folsom, Sponsorship
Zewen Zhu Finance Consultant
Caesar Ho, Scholarship
2014 Board and Advisor
Dr. Michelle Chen, President Dr. Chen is a biotech entrepreneur & executive with extensive experience in biopharma, diagnostics and life sciences. She has a track record of successful leadership roles in business development, marketing and R&D. Most recently she was a business development executive at Hoffmann-La Roche responsible for global oncology licensing, collaborations and M&A. Prior to this role, she was involved in the personalized medicine effort for Roche. Dr. Chen started her biotech career in early drug discovery& development at Scios and later Abgenix as a group leader working on the assay development of antibody drugs. She then went on to gain commercial experience at Agilent Technologies and Applied Biosystems respectively. Dr. Chen received a PhD in Biochemistry from the University of Washington, followed by the post-doctoral work at UCSF and bioinformatics training at Stanford University. She has been a CBA board member, advisor and volunteer in the last five years and a FAST program advisor for BayBio dedicated to help biotech start-ups grow and succeed.
Dr. Patty Kiang, Vice-President Dr. Kiang is a Biopharmaceutical Consultant on Quality Systems and Delivery Devices. She was Director of Business Development for Catalent Pharmaceutical Solutions’west coast operation, prior to Catalent, she was Head of Device Development for Genentech Inc. in South San Francisco, CA. She was responsible for the development of various injection devices and Extractable / Leachable program for evaluation of primary container/closure systems. Prior to joining Genentech, she was Director, Sterile Injectable Delivery Device and Packaging Support for Schering Plough, in Kenilworth, NJ. She also had various positions at West Pharmaceutical Services in Exton, PA, as Director of Technology Development, and Director of Quality Control and Method development. She is a member of the faculty of the PDA’s Training and Research Institute, where she teaches courses on Prefilled Syringe& injection devices, Extractables / leachables, and Parenteral Packaging; she served as a member of USP’s Expert Committee on Drug Packaging, Storage and Distribution. She was the chairperson for PDA Gamma Radiation Sterilization of Polymeric Materials Committee. She is an expert in the area of drug and container / closure interactions and compatibility issues. She was the President of Chinese Bioscience Association in 2011. She holds five patents in the field of polymeric surface coatings and received a Ph.D. in Analytical Chemistry from Villanova University and an MBA from Pennsylvania State University.
Dr. Lin Sun-Hoffman, Advisor Dr. Sun-Hoffman is a licensed patent attorney and advises on issues related to intellectual property and technology transfer matters. She also consults on biotechnology and pharmaceutical business-related matters. She helps businesses expand into China through providing strategic and practical advice on issues as diverse as government relations, research and/or business partnerships between Chinese and American companies, intellectual property protection and drug regulatory matters. She previously worked for Life Technologies/ABI, BIO, Celera Genomics, US Patent and Trademark Office and National Institutes of Health. She is the former president of Chinese Biopharmaceutical Association based in Washington DC, currently serves on board of US China Green Energy Council, a member of Bayhelix. Dr. Sun-Hoffman has a PhD in Biochemistry/Cell and Molecular Biology. She was the president of CBA 2013.
Dr. Katherine Wang, Treasurer Katherine Wang got her B.S. degree in Optics from Shandong University, and Ph.D. in Physics from Syracuse University. She worked as research scientist in Neurodegenerative Diseases Center of University of Virginia. She has years of Hands-on experiences in optical engineering, DNA sequencing, protein purification, drug-protein interactions and cell culture. Professionally trained as physicist, later she discovered that her real interest is in clinical data analysis. She is currently doing statistical programming after she led clinical programming projects at Gilead Sciences for around two years. Previously she worked as certified advanced SAS programmer and data manager as well in Clinovo. Katherine’s diligent work and enthusiasm have been well recognized. She enjoys reading, writing and Scottish Country Dancing.
Ms. Cindy Liu, Publications Cindy received her M.S. in Biochemistry from University of Maryland. She has over 15 years of working experience in academic, biotech and biopharmaceutical industries, focusing on protein chemistry, assay development, and quality system. Currently she is a supervisor of quality control-bioanalytics at Solstice Neurosciences (a US WorldMeds comapny). Prior to Solstice, she worked at SynPep, Universityof California, Bionetics, and University of Maryland. Cindy has been a CBA board member and volunteer in the past few years. For leisure, she likes photography, gardening and music.
Mr. Frank Lin, Taiwan Liaison Mr. Frank Lin is the Regional Sales Marketing Director at Specialdeals.com, a VC funded startup a deal-of-the-day website that features discounted gift certificates usable at local or national companies. Frank Lin is the Regional Marketing Director in US and General Manager in Asia Pacific at Matchbin, Inc, a Web 2.0 Content Management System (CMS) provider for newspaper/radio station/magazine industry. Prior to that, Mr. Lin was a Sales Operation / Marketing Specialist at VeriSilicon, a Fabless Semiconductor company. Mr. Lin now is the Marketing Manager at GBC (www.gbc.com.tw). Mr. Lin received his B.A. degree in Electrical and Computer Engineering from Purdue University and an MBA from Santa Clara University.
Mr. Andrew Teng, Taiwan Liaison Currently acting as C.S.O. at Sunwell Scientific Inc. Mr. Teng has more than 16 years of general management experience in the fields of semiconductor and Bio Science. His broad background includes P&L, operational, BD, product development, marketing, IP protection and M&A. He was a Managing Director at Ecos Lab Co. Prior to joining Ecos Lab, Mr. Teng held a senior positions with Encepho Pharmaceutical as V.P. of Business Development. Mr. Teng has extensive international experience having had direct responsibility for business development and strategic planning in Greater China. Mr. Teng has a B.S. degree from San Jose State University. Currently studying PhD in Industrial Economics at Jinan University, China.
Dr. Patrick Yang, Alliance Dr. Patrick Yang is currently Principal Scientist at Relypsa, Inc. He has been working in bay area for many years in various pharmaceutical companies in the field of CMC/analytical development. Dr. Yang obtained his Ph. D. in pharmaceutical sciences from University of the Pacific, USA. He has previously served on CBA board several terms.
Dr. Kai Zheng, Membership Dr. Kai Zheng received his Ph.D. from the Department of Pharmaceutical Chemistry at the University of Kansas. After graduation, he joined Genentech Oceanside site and focused on the protein formulation development at early stages. After working at Oceanside for 4 years, he moved to Genentech SSF site and joined the late stage pharmaceutical development department. He is working on Phase III and commercial formulation development now. When he was in Oceanside, he was a member of SABPA (Sino-American Biomedical and Pharmaceutical Professionals Association) and worked as meeting volunteers.
Dr. Pengguang Wu, E-communication Dr. Wu is interested in healthcare, mobile health, and internet of things. He previously worked at Exelixis in the area of assay development, high throughput screening, compound management, and translational medicine biorepository in oncology. Proior to that, he worked at Tularik in assay development, screening, and lead optimization in anti-infectives, immunology/inflammation, and oncology. He obtained his BSc in chemistry from Shandong University, China. His PhD was in physical chemistry of nucleic acid/drug complex from the Department of Chemistry, University of Washington, Seattle. He did a postdoc studying DNAs with modified bases in the Departments of Physics and Biophysics at University of Rochester, Rochester, New York. He did another postdoc studying protein folding in the Department of Biology, Johns Hopkins University, Baltimore, MD.
Mark Chen, Secretary
Hui Fang Li, Press relationship
Jing Folsom, Sponsorship
Caesar Ho, Scholarship